A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies

Inclusion Criteria:

* Non-hematologic malignancy that has progressed or no standard therapy is known
* Four weeks from last chemotherapy or two weeks from last non-cytotoxic therapy
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
* No more than 3 prior chemotherapy regimens in advanced/metastatic setting
* Absolute neutrophil count \>=1,500/mm3 and platelets \>=100,000/mm3
* Bilirubin \<=1.5 x Upper Limit of Normal (ULN), Aspartate aminotransferase \<=2.5 x ULN
* Serum creatinine \<=1.5 x ULN
* Men and women \>=18 years
* Women of Child Bearing Potential (WOCBP) must use adequate method of contraception throughout and up to 4 weeks after the study

Exclusion Criteria:

* WOCBP and men not using adequate method of birth control
* WOCBP who are pregnant or breastfeeding
* Prior radiation \>=25% of bone marrow containing skeleton
* Uncontrolled, significant, or active cardiovascular or pulmonary disease or infection or psychiatric disorder
* Neuropathy
* Active brain metastases
* Inability to swallow capsules
* History of gastrointestinal disease, surgery or malabsorption, or requiring use of a feeding tube
* Concurrent chemotherapy, hormonal therapy, immunotherapy, or radiotherapy